Copenhagen, Capital Region of Denmark, Denmark
I am a dedicated and purpose-driven Lab Director with more than 15 years of experience in the biotechnology and pharmaceutical sectors. My leadership spans clinical laboratory operations, regulatory compliance, and translational biomarker science — all rooted in a passion for improving healthcare outcomes and empowering high-performing teams. Currently, I lead a CAP/CLIA/ISO-accredited, GMP/GCP/GCLP-compliant Clinical Laboratory, where I oversee the daily operations and strategic development of laboratory services. I manage a multidisciplinary team of over 50 professionals, driving excellence across biomarker testing, regulatory adherence, and scientific innovation. My focus is on integrating digital solutions, optimizing workflows, and ensuring that every test result contributes to meaningful clinical and scientific insights. With a Ph.D. in Health Sciences from the University of Copenhagen, I bring a strong foundation in scientific rigor and data integrity. I am deeply committed to delivering reliable, bias-free, and validated biomarker data that supports drug development and precision medicine. Understanding that biomarkers are central to advancing personalized healthcare, I emphasize the importance of supporting the full biomarker journey — from RUO today to IVD tomorrow — to ensure our assays remain both clinically relevant and technically robust. As the exclusive provider of Nordic Bioscience’s ECM biomarker portfolio, our lab stands apart through its scientific depth, validated platforms, and commitment to quality across all study phases. Through strategic leadership and a collaborative mindset, I work to inspire teams, enhance client partnerships, and translate scientific complexity into operational excellence. Whether navigating evolving regulatory landscapes or supporting first-in-human trials, I am driven by a shared mission: to make a measurable impact on patient care and health innovation. Let’s connect if you are passionate about biomarker science, clinical lab excellence, or transforming data into decisions that matter.
Responsible for the overall operation and administration of laboratory services and to ensure that business objectives are met efficiently and effectively. - Manage laboratory services under GCP/GCLP regulation and CAP accreditation - Biochemical markers validations in accordance with CLSI and EMA guidelines - Interact closely with pharmaceutical companies/clients for plan, execute and monitor projects - Internal lead for external audits - Digitalization and automation of laboratory operations - Contribute to corporate strategy in the area of Laboratory services to ensure that short and long-term objectives are achieved - Manager of 60 employees and several cross-functional teams
- leading the biomarker efforts in hemophilia - designing and developing novel biomarkers quantifying disease-specific protein fragments of hemostasis and wound healing
- Produce and validate biochemical markers under GMP and in accordance with CLSI and EMA guidelines - QA Manager for the bioanalytical laboratory under GCP/GCLP regulation and CAP accreditation standards - Internal lead for external audits by sponsor, BUREAU VERITAS, arbejdstilsynet, Herlev kommune - Manager of 28 employees and several cross-functional teams
Review and approval of laboratory books (molecular biology and chemistry)
Addressing the function of proteoglycans (syndecans, biglycan, decorin) in inflammatory diseases using transgenic mice. Also responsible for design and production of neutralizing antibodies against biglycan-mediated-TLRs signalling.
Addressing important area of cell surface proteoglycan receptors research with relevance for tumour biology. This was done through analyze proteolytic cleavage products for syndecan-1 and syndecan-4, generating monoclonal antibodies that specifically recognize the cleavage product but not the core protein, and to use these antibodies to stain for specific syndecan cleavage products in tumour biopsies
Inducible mammalian expression of insulin and IGF-1 receptors: effect of receptor dosage on insulin signalling